Skip to content

Study · Not a test of the peptide alone · 2015

3 results

NMDA-type glutamate receptors participate in reduction of food intake following hindbrain melanocortin receptor activation.

Campos CA, Ritter RC

American journal of physiology. Regulatory, integrative and comparative physiology12 Nov 2014Cited by 19 (Europe PMC)

PMID25394828 (opens in a new tab)PMCIDPMC4281681 (opens in a new tab)DOI10.1152/ajpregu.00388.2014 (opens in a new tab)PepBankPUB-25394828
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Efficacy outcome

    In adult male rats, coinjecting the NMDAR antagonist d-CPP-ene with MTII into the fourth ventricle or the nucleus of the solitary tract attenuated the MTII-induced reduction of food intake.

    In plain wordsIn rats, blocking NMDA receptors in the hindbrain weakened the food-intake reduction caused by melanotan II.

    Peptide
    Melanotan II
    Outcome
    DecreaseMTII-induced reduction of food intake with NMDAR antagonist
    Study

    ratn: not reported in source

    Comparator
    MTII alone
    Outcome group
    Appetite and food intake · Nervous system and cognition

    Source sentences

    Summary
    We found that coinjection of a competitive NMDAR antagonist (d-CPP-ene) with MTII into the fourth ventricle or directly into the NTS of adult male rats attenuated MTII-induced reduction of food intake.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 02AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, hindbrain NMDAR antagonism attenuated MTII-induced ERK1/2 phosphorylation in NTS neurons.

    In plain wordsIn rats, blocking hindbrain NMDA receptors reduced a cell signal (ERK1/2 phosphorylation) that melanotan II normally triggers.

    Peptide
    Melanotan II
    Outcome
    DecreaseMTII-induced ERK1/2 phosphorylation in NTS neurons with NMDAR antagonist
    Study

    ratn: not reported in source

    Comparator
    MTII alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Hindbrain NMDAR antagonism also attenuated MTII-induced ERK1/2 phosphorylation in NTS neurons

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  3. 03AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In rats, hindbrain NMDAR antagonism prevented synapsin I phosphorylation in central vagal afferent endings during MTII treatment.

    In plain wordsIn rats, blocking hindbrain NMDA receptors prevented a nerve-ending signal (synapsin I phosphorylation) during melanotan II treatment.

    Peptide
    Melanotan II
    Outcome
    DecreaseMTII-induced synapsin I phosphorylation in vagal afferent endings with NMDAR antagonist
    Study

    ratn: not reported in source

    Comparator
    MTII alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    prevented synapsin I phosphorylation in central vagal afferent endings

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.